We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Chronic HCV Increases Risk for Renal Cancer

By LabMedica International staff writers
Posted on 19 Jul 2010
An enzyme-linked immunoassay (ELISA) and a molecular assay for ribonucleic acid (RNA) were used to test a large cohort for a specific viral infection. More...


The cohort was tested for the presence of antibodies to Hepatitis C virus (HCV) and their infectivity by the molecular test to establish their risk for renal cell carcinoma (RCC).

The 67,063 participants were tested for HCV between 1997 and 2006, and followed to monitor development of RCC until April 2008 and about 5% were positive for the virus. RCC developed in 17 of the 3,057 (0.6%) who were HCV positive and in only 0.3% of 64,006 HCV negative participants. Among the HCV-positive RCC patients, the HCV RNA viral levels and genotypes, and liver histology were recorded.

The RCC cases in HCV positive patients included eight clear cell cancers, six papillary cancers, two mixed clear cell/papillary, and one undifferentiated neoplasm.

Among participants diagnosed with RCC, HCV positive patients were of a significantly younger average age than HCV negative patients were. Men were 2.4 times more likely to develop the malignancy than women were, and Afro-Americans had about a 40% higher risk than any other racial or ethnic group.

Chronic hepatitis C is primarily a disease of the liver, but it can also contribute to problems elsewhere in the body. Stuart C. Gordon, M.D., from Henry Ford Hospital, (Detroit, MI, USA) said, "These results add to growing literature that shows that the hepatitis C virus causes disease that extends beyond the liver, and in fact most of our HCV-infected kidney cancer patients had only minimal liver damage". The results were published in the April 2010 issue of Cancer Epidemiology Biomarkers and Prevention.

Related Links:

Henry Ford Hospital



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.